Levoleucovorin

Carcinoid Tumor

Hospices Civils de LyonPhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 95/ 100

Competitive context

9 Active assets in the Carcinoid Tumor cohort.

Asset / Sponsor	Phase	Rating
Everolimus RayzeBio, Inc.	Phase 3	B
DOTATOC British Columbia Cancer Agency	Phase 2	B
Pasireotide H. Lee Moffitt Cancer Center and Research Institute	Phase 2	B
Axitinib H. Lee Moffitt Cancer Center and Research Institute	Phase 2	B
Bms-907351 Fox Chase Cancer Center	Phase 2	B

View all 14 →

Same molecule, other indications

Levoleucovorin is also rated in:

gastroesophageal junction adenocarcinomaDormant

BB

Indicative ·

68 / 100

Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant

BB

Indicative ·

68 / 100

colorectal cancerDormant

BB

Indicative ·

68 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.